Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Verastem, Inc. - Common Stock
(NQ:
VSTM
)
5.740
+0.780 (+15.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verastem, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer
October 14, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 06, 2023
From
Verastem Oncology
Via
Business Wire
Analyst Ratings for Verastem
September 27, 2023
Via
Benzinga
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
September 28, 2023
From
Verastem Oncology
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
September 27, 2023
Via
Benzinga
Truist Securities Maintains Buy Rating for Verastem: Here's What You Need To Know
July 11, 2023
Via
Benzinga
Verastem Stock Is Outperforming 92% Of The Market — And It Just Surged
June 15, 2023
The company is testing a treatment for a form of ovarian cancer.
Via
Investor's Business Daily
Verastem Oncology to Participate in Upcoming Investor Conferences
September 05, 2023
From
Verastem Oncology
Via
Business Wire
3 Penny Stocks That Can Triple Your Money in the Next 12 Months
September 04, 2023
Although penny stocks are among the most speculative asset classes, these wagers just happen to have strong analyst backing.
Via
InvestorPlace
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
September 02, 2023
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet...
Via
Talk Markets
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
August 28, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 08, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
July 11, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
July 05, 2023
From
Verastem Oncology
Via
Business Wire
Why Clene Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
June 16, 2023
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) shares gained 192.8% to $0.2427 in pre-market trading. Evelo Biosciences was granted U.S. patent #11672834 for "Prebiotic Compositions And Methods Of Use...
Via
Benzinga
Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
June 16, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 15, 2023
From
Verastem Oncology
Via
Business Wire
Crude Oil Rises Sharply; Jabil Posts Upbeat Q3 Results
June 15, 2023
U.S. stocks traded higher toward the end of trading, with Dow Jones gaining around 450 points on Thursday. The Dow traded up 1.32% to 34,429.39 while the NASDAQ rose 1.27% to 13,799.28. The S&P 500,...
Via
Benzinga
Verastem's Ovarian Cancer Drug Showing Promise, Analyst Upgrades Stock
June 15, 2023
Mizuho Securities has upgraded Verastem Inc (NASDAQ: VSTM) from Neutral to Buy with a price target of $36, up from $24, to
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
June 15, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
June 15, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 15, 2023
Via
Benzinga
Verastem To Rally Around 287%? Here Are 10 Other Analyst Forecasts For Thursday
June 15, 2023
Piper Sandler boosted the price target for Accenture plc (NYSE: ACN) from $250 to $316. Piper Sandler analyst Arvind Ramnani upgraded the stock from Underweight to Neutral. Accenture shares rose 1.1%...
Via
Benzinga
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN
June 05, 2023
Via
AB Newswire
AI Boom Wanes In June: Nvidia Falls Under $1T As Benzinga Reviews May's Champions
June 01, 2023
Via
Benzinga
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
June 01, 2023
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END
Via
FinancialNewsMedia
Verastem Oncology Announces Reverse Stock Split
May 31, 2023
From
Verastem Oncology
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
May 29, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.